Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Link to the Inserm press review  (in French)

J.-L. Mas, G. Derumeaux, B. Guillon, E. Massardier, H. Hosseini, L. Mechtouff, C. Arquizan, Y. Béjot, F. Vuillier, O. Detante, C. Guidoux, S. Canaple, C. Vaduva, N. Dequatre‑Ponchelle, I. Sibon, P. Garnier, A. Ferrier, S. Timsit, E. Robinet‑Borgomano, D. Sablot, J.-C. Lacour, M. Zuber, P. Favrole, J.-F. Pinel, M. Apoil, P. Reiner, C. Lefebvre, P. Guérin, C. Piot, R. Rossi, J.-L. Dubois‑Randé, J.-C. Eicher, N. Meneveau, J.-R. Lusson, B. Bertrand, J.-M. Schleich, F. Godart, J.-B. Thambo, L. Leborgne, P. Michel, L. Pierard, G. Turc, M. Barthelet, A. Charles‑Nelson, C. Weimar, T. Moulin, J.-M. Juliard, and G. Chatellier, for the CLOSE Investigators*



Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared
with antiplatelet therapy.


In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet
therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.


A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 23 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet- only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P<0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P = 0.02). The number of serious adverse events did not differ significantly between the treatment groups (P = 0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.


Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE number, NCT00562289.)

This part of the website could either be in French or English, depending on the sources of the actualities.

Autres Publications

 04 octobre 2017
 20 septembre 2017
Soluble Amyloid Precursor Protein Alpha Interacts with alpha3-Na, K-ATPAse to Induce Axonal Outgrowth but Not Neuroprotection: Evidence for Distinct Mechanisms Underlying these Properties
 19 septembre 2017
Transient increase in sAPPa secretion in response to Ab1e42 oligomers: an attempt of neuronal self-defense?
 11 septembre 2017
Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol.
 01 juin 2017
Targeting demyelination via α-secretases promoting sAPPα release to enhance remyelination in central nervous system
 19 avril 2017
Spastin regulates VAMP7-containing vesicles trafficking in cortical neurons.
 05 avril 2017
Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice.
 14 mars 2017
Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development.
 07 mars 2017
Does virtual reality have a future for the study of episodic memory in aging?
 22 février 2017
Can a 15-sec FLAIR replace conventional FLAIR sequence in stroke MR protocols?
 22 février 2017
Is Unexplained Early Neurological Deterioration After Intravenous Thrombolysis Associated With Thrombus Extension?
 20 février 2017
Bi-directional interplay between proximal and distal inputs to CA2 pyramidal neurons.
 15 février 2017 16 février 2017
The distinctive role of executive functions in implicit emotion regulation.
 11 février 2017
Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?
 31 janvier 2017
Neuropsychological improvement after posterior fossa arachnoid cyst drainage.
 26 janvier 2017
Phenotypic continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of Social Cognition (MASC).
 19 janvier 2017
Potentiation of Amitriptyline Anti-Hyperalgesic-Like Action By Astroglial Connexin 43 Inhibition in Neuropathic Rats
 18 janvier 2017
Impact of DRD2/ANKK1 and COMT Polymorphisms on Attention and Cognitive Functions in Schizophrenia.
 15 janvier 2017
Netrin G1: its downregulation in the nucleus accumbens of cocaine-conditioned mice and genetic association in human cocaine dependence.
 07 janvier 2017
Does COMT val158met polymorphism influence P50 sensory gating, eye tracking or saccadic inhibition dysfunctions in schizophrenia?